|
Drug Interactions in Oncology Patients Receiving Tyrosine Kinase Inhibitors
|
|
| Author:
|
, HRIDYA JAYAMOHANAN, GOPIKA S KUMAR, DIVYA V NAIR, NAVYA JOSE, UMA DEVI P, PAVITHRAN K
|
| Abstract:
|
Objective: To identify and evaluate the drug-drug interactions (DDIs) associated with tyrosine kinase inhibitors (TKIs) among oncology patients with solid tumours.
Methods: One hundred and twenty adult patients with solid tumours prescribed TKI therapy were enrolled in the 7 months study. Demographic and medication details were obtained from the patient's medical records and patient interview. Lexicomp® Interaction Module was used for the assessment of the severity of
interactions between TKIs and concomitant medications.
Results: Eighty six out of 120 patients enrolled in this study showed at least one DDI. Among the 89 DDIs observed during the study period, 67% (n = 60) belonged to D category while the remaining belonged to X category (n = 29). Among the TKIs, gefitinib (42%, n=37 ) followed by pazopanib (30%, n= 27) contributed to
the majority of drug interactions. The most frequently observed drug interactions were between TKIs and gastric acid-suppressive agents like pantoprazole, ranitidine, rabeprazole, magnesium hydroxide and omeprazole which constituted 73% of the drug interactions. Interventions or recommendations for the
management of these DDIs were put forward, including spacing between the TKI and concomitant medication during administration and alternatives for treatment. Tyrosine kinase inhibitors have become an integral part of oncology practice, but there are many challenges like DDIs, which can affect the clinical outcomes. Hence, the identification and management of these DDIs are essential for improving the clinical outcome and quality of life of the patient. As a result, closer collaboration between oncologists and clinical pharmacists is necessary for the optimization of the treatment.
|
| Keyword:
|
Oncology, tyrosine kinase inhibitor, drug-drug interaction, gastric acid suppressants.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2021.13.02.100
|
| Download:
|
Request For Article
|
|
|